Aqara Camera Hub G5 Pro Released to Global Markets
The feature-packed security camera doubles as a smart home hub for outdoor spaces
Aqara, a global leader and pioneer in IoT, announced today the global availability of its first surveillance camera designed for the outdoors. The Camera Hub G5 Pro combines superior image quality, advanced AI capabilities, and seamless smart home integration, providing homeowners with enhanced security day and night.
With a sleek design in two finishes, the G5 Pro delivers 2.6K Quad HD recording with True Color Night Vision, ensuring crystal-clear images even in the darkest night. Equipped with on-device AI, the camera captures critical events around the home and alerts homeowners of potential threats, such as lingering individuals or package theft. It can even trigger automation to deter intruders. Additionally, the G5 Pro works with popular smart home platforms and supports the RTSP protocol, making it easy to integrate into users’ existing smart security systems.
More than just a security camera, the G5 Pro serves as a multi-protocol hub for outdoor space, expanding the reach and reliability of your smart home network. As a Matter Controller, Thread Border Router and Aqara Matter bridge/Zigbee hub, it can connect and manage not only Aqara accessories but also third-party Matter devices, making it an ideal foundation for DIY users looking to create their own home security systems.
Other highlights of the Camera Hub G5 Pro include:
- Premium Image Clarity: The G5 Pro features True Color Night Vision and provides 4MP resolution (1520p) and a 133° field of view, ensuring clear images in low-light conditions. Its f/1.0 aperture captures up to four times more light than traditional f/2.0 lenses, while the graphene-cooled 1/1.8" sensor enhances low-lit performance. A dimmable spotlight and a 100 dB speaker add extra security by acting as an intruder deterrent and enabling two-way audio communication.
- Local AI Detection for Security and Automation: The G5 Pro is equipped with a built-in NPU (neural processing unit) to enable on-device AI object detection and sound detection. Simultaneously it can recognize faces and vehicles, as well as detect people, packages, animals and even camera lens obstructions. These local AI capabilities allow the camera to capture critical events and trigger automation, even during internet outages.
- Seamless Integration with Major Platforms: The G5 Pro integrates seamlessly with Apple Home, and is among the few HomeKit Secure Video cameras to support PoE and True Color Night Vision. It also streams to smart displays that are compatible with Alexa, Google Home or SmartThings. With added RTSP support, the G5 Pro can stream to third-party clients including Home Assistant over a local area network, and is compatible with RTSP-enabled video servers.
- Enhanced Privacy with End-to-End Encryption: The G5 Pro supports end-to-end encryption for live and recorded video, ensuring that only homeowners and their family can access the footage. Its eMMC storage can sync to cloud storage services provided by Aqara and iCloud, and also supports local NAS system backups for added security.
- Flexible Connectivity: Available in both PoE and Wi-Fi versions, the G5 Pro offers flexible connectivity options for various environments. The PoE version features an uninterrupted Ethernet connection with Power-over-Ethernet support, while the Wi-Fi version supports dual-band Wi-Fi (2.4GHz/5GHz) with WPA3 security.
- Weather-Resistant and Durable Design: With an IP65-rated weather-resistant design, the G5 Pro can withstand extreme temperatures (from -30°C/-22°F to 50°C/122°F) and resist moisture and dust. It’s built to operate in any outdoor condition, ensuring year-round protection for your home.
“The launch of the Camera Hub G5 Pro marks a step forward in providing homeowners with a comprehensive, reliable and versatile smart home solution,” said Cathy You, Aqara Senior Vice President of Global Business and Strategy. “With this new camera, we’ve pushed the boundaries of outdoor security. It isn’t just a security camera—it’s a smart home hub that connects your outdoor spaces with the rest of your home, offering a seamless, connected experience from the inside out.”
The Aqara Camera Hub G5 Pro is now available globally and can be purchased through Aqara’s official website, authorized retailers, and major e-commerce platforms such as Amazon (Canada, France, Germany, Italy, Netherlands, Poland, Spain, UK, US).
For more information on the new camera, please visit our website.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250220387891/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release
- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom